A comprehensive immunohistochemical analysis of 26 markers in
250 cases of serous ovarian tumors

J 2023

A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors

NEMEJCOVA, Kristyna, Adam SAFANDA, Michaela Kendall BARTU KENDALL, Romana MICHALKOVA, Jana DROZENOVA et. al.

Základní údaje

Originální název

A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors

Autoři

NEMEJCOVA, Kristyna (203 Česká republika, garant), Adam SAFANDA (203 Česká republika), Michaela Kendall BARTU KENDALL (203 Česká republika), Romana MICHALKOVA (203 Česká republika), Jana DROZENOVA (203 Česká republika), Pavel FABIAN (203 Česká republika), Jitka HAUSNEROVÁ (203 Česká republika, domácí), Jan LACO (203 Česká republika), Radoslav MATEJ (203 Česká republika), Gabor MEHES (203 Česká republika), Petr SKAPA (203 Česká republika), Ivana STRUZINSKA (203 Česká republika) a Pavel DUNDR (203 Česká republika)

Vydání

DIAGNOSTIC PATHOLOGY, LONDON, BMC, 2023, 1746-1596

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30109 Pathology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.600 v roce 2022

Kód RIV

RIV/00216224:14110/23:00130655

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1186/s13000-023-01317-9

UT WoS

000941171800001

Klíčová slova anglicky

Ovarian tumors; Tubo-ovarian tumors; High grade serous carcinoma; Low grade serous carcinoma; Immunohistochemistry

Štítky

14110230, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 12. 1. 2024 13:27, Mgr. Tereza Miškechová

Anotace

V originále

BackgroundWe examined a large cohort of serous tubo-ovarian tumors with 26 immunohistochemical markers, with the aim to assess their value for differential diagnosis and prognosis.MethodsImmunohistochemical analyses with 26 immunomarkers were performed on 250 primary tubo-ovarian tumors including 114 high grade serous carcinomas (HGSC), 97 low grade serous carcinomas (LGSC), and 39 serous borderline tumors (micropapillary variant, mSBT). The associations of overall positivity with clinicopathological characteristics were evaluated using the chi-squared test or Fisher's Exact test.ResultsWe found significantly different expression of p53, p16, ER, PR, PTEN, PAX2, Mammaglobin, RB1, Cyclin E1, stathmin, LMP2, L1CAM, CD44, and Ki67 in HGSCs compared to LGSCs. No significant differences were found between LGSC and mSBT. None of the other included markers (PAX8, ARID1A, HNF1B, Napsin A, CDX2, SATB2, MUC4, BRG1, AMACR, TTF1, BCOR, NTRK) showed any differences between the investigated serous tumors. Regarding the prognosis, only PR and stathmin showed a statistically significant prognostic meaning in LGSCs, with better overall survival (OS) and recurrence-free survival (RFS) in cases positive for PR, and worse outcome (RFS) for stathmin. None of the study markers showed prognostic significance in HGSCs.ConclusionWe provided an extensive immunohistochemical analysis of serous ovarian/tubo-ovarian tumors. Although we found some differences in the expression of some markers in HGSCs compared to LGSCs, only p53, p16, and Ki67 seem to be useful in real diagnostic practice. We also suggested the best discriminative cut-off for Ki67 (10% of positive tumor cells) for distinguishing HGSC from LGSC. We found prognostic significance of PR and stathmin in LGSCs. Moreover, the high expression of stathmin could also be of predictive value in ovarian carcinomas as target-specific anti-stathmin effectors are potential therapeutic targets.

Návaznosti

90233, velká výzkumná infrastruktura

Název: BBMRI.cz IV

Citovat

NEMEJCOVA, Kristyna, Adam SAFANDA, Michaela Kendall BARTU KENDALL, Romana MICHALKOVA, Jana DROZENOVA, Pavel FABIAN, Jitka HAUSNEROVÁ, Jan LACO, Radoslav MATEJ, Gabor MEHES, Petr SKAPA, Ivana STRUZINSKA a Pavel DUNDR. A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors. DIAGNOSTIC PATHOLOGY. LONDON: BMC, 2023, roč. 18, č. 1, s. 1-12. ISSN 1746-1596. Dostupné z: https://dx.doi.org/10.1186/s13000-023-01317-9.

@article{2278170,
   author = {Nemejcova, Kristyna and Safanda, Adam and Bartu Kendall, Michaela Kendall and Michalkova, Romana and Drozenova, Jana and Fabian, Pavel and Hausnerová, Jitka and Laco, Jan and Matej, Radoslav and Mehes, Gabor and Skapa, Petr and Struzinska, Ivana and Dundr, Pavel},
   article_location = {LONDON},
   article_number = {1},
   doi = {http://dx.doi.org/10.1186/s13000-023-01317-9},
   keywords = {Ovarian tumors; Tubo-ovarian tumors; High grade serous carcinoma; Low grade serous carcinoma; Immunohistochemistry},
   language = {eng},
   issn = {1746-1596},
   journal = {DIAGNOSTIC PATHOLOGY},
   title = {A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors},
   url = {https://diagnosticpathology.biomedcentral.com/articles/10.1186/s13000-023-01317-9},
   volume = {18},
   year = {2023}
}

TY  - JOUR
ID  - 2278170
AU  - Nemejcova, Kristyna - Safanda, Adam - Bartu Kendall, Michaela Kendall - Michalkova, Romana - Drozenova, Jana - Fabian, Pavel - Hausnerová, Jitka - Laco, Jan - Matej, Radoslav - Mehes, Gabor - Skapa, Petr - Struzinska, Ivana - Dundr, Pavel
PY  - 2023
TI  - A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors
JF  - DIAGNOSTIC PATHOLOGY
VL  - 18
IS  - 1
SP  - 1-12
EP  - 1-12
PB  - BMC
SN  - 17461596
KW  - Ovarian tumors
KW  - Tubo-ovarian tumors
KW  - High grade serous carcinoma
KW  - Low grade serous carcinoma
KW  - Immunohistochemistry
UR  - https://diagnosticpathology.biomedcentral.com/articles/10.1186/s13000-023-01317-9
N2  - BackgroundWe examined a large cohort of serous tubo-ovarian tumors with 26 immunohistochemical markers, with the aim to assess their value for differential diagnosis and prognosis.MethodsImmunohistochemical analyses with 26 immunomarkers were performed on 250 primary tubo-ovarian tumors including 114 high grade serous carcinomas (HGSC), 97 low grade serous carcinomas (LGSC), and 39 serous borderline tumors (micropapillary variant, mSBT). The associations of overall positivity with clinicopathological characteristics were evaluated using the chi-squared test or Fisher's Exact test.ResultsWe found significantly different expression of p53, p16, ER, PR, PTEN, PAX2, Mammaglobin, RB1, Cyclin E1, stathmin, LMP2, L1CAM, CD44, and Ki67 in HGSCs compared to LGSCs. No significant differences were found between LGSC and mSBT. None of the other included markers (PAX8, ARID1A, HNF1B, Napsin A, CDX2, SATB2, MUC4, BRG1, AMACR, TTF1, BCOR, NTRK) showed any differences between the investigated serous tumors. Regarding the prognosis, only PR and stathmin showed a statistically significant prognostic meaning in LGSCs, with better overall survival (OS) and recurrence-free survival (RFS) in cases positive for PR, and worse outcome (RFS) for stathmin. None of the study markers showed prognostic significance in HGSCs.ConclusionWe provided an extensive immunohistochemical analysis of serous ovarian/tubo-ovarian tumors. Although we found some differences in the expression of some markers in HGSCs compared to LGSCs, only p53, p16, and Ki67 seem to be useful in real diagnostic practice. We also suggested the best discriminative cut-off for Ki67 (10% of positive tumor cells) for distinguishing HGSC from LGSC. We found prognostic significance of PR and stathmin in LGSCs. Moreover, the high expression of stathmin could also be of predictive value in ovarian carcinomas as target-specific anti-stathmin effectors are potential therapeutic targets.
ER  -

NEMEJCOVA, Kristyna, Adam SAFANDA, Michaela Kendall BARTU KENDALL, Romana MICHALKOVA, Jana DROZENOVA, Pavel FABIAN, Jitka HAUSNEROVÁ, Jan LACO, Radoslav MATEJ, Gabor MEHES, Petr SKAPA, Ivana STRUZINSKA a Pavel DUNDR. A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors. \textit{DIAGNOSTIC PATHOLOGY}. LONDON: BMC, 2023, roč.~18, č.~1, s.~1-12. ISSN~1746-1596. Dostupné z: https://dx.doi.org/10.1186/s13000-023-01317-9.

Podrobný výpis o publikaci